A Phase I Study of Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)
概览
- 阶段
- 不适用
- 干预措施
- 46 Gy Radiation Therapy
- 疾病 / 适应症
- Head and Neck Cancer
- 发起方
- Medical College of Wisconsin
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- The number of subjects with a dose-limiting toxicity related to perioperative complication rates.
- 状态
- 进行中（未招募）
- 最后更新
- 上个月
概览
简要总结
This is a phase 1 study to determine the safety of a condensed preoperative radiation regimen (10, 7, or 5 fractions) for the management of head and neck squamous cell carcinoma.
详细描述
All subjects in this study will receive pre-operative hypofractionated radiation therapy, which will be subject to fractionation reduction, that being 10 fractions, 7 fractions, or 5 fractions, as compared to 30 fractions of conventional radiation therapy. All patients will subsequently undergo surgery for resection of remaining disease at the primary site and at-risk nodal basins 6-8 weeks after completion of radiation. The subjects will receive smaller number of fractions (total visits) but with a higher dose of radiation with each Dose Level. Participants will receive a total radiation dose of 46 Gy in 10 fractions (Dose Level 1), 40 Gy in 7 fractions (Dose Level 2), or 35 Gy in 5 fractions (Dose Level 3), depending on the assigned experimental total fractions. Radiation will be delivered using intensity modulated radiation therapy (IMRT) with a daily cone-beam CT for five days a week, for less than two weeks depending on the assigned dose level at the time of enrollment. Due to the novelty of translational data and non-dependency on the primary endpoint, presentation and publication in a scientific journal of the translational endpoints may precede publication of the primary endpoint.
研究者
Joseph Zenga
Assistant Professor
Medical College of Wisconsin
入排标准
入选标准
- •Patients 18 years or older with surgically resectable, Human papillomavirus (HPV) -negative squamous cell carcinoma of the head and neck (squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, nasal cavity or paranasal sinuses). Resectability will be determined by the treating surgeon. Patients must have locoregionally advanced disease defined by clinical T3-4 staging and/or clinical node positive staging. Patients may also be eligible if they meet one of the following criteria:
- •Clinical T2N0 disease with perineural invasion identified on a pretreatment biopsy.
- •Clinical T2N0 disease with lymphovascular space invasion identified on a pretreatment biopsy.
- •Clinical T2N0 oral cavity cancer with clinical, biopsy, or radiographic depth of invasion of at least 5 mm.
- •Zubrod performance status 0-
- •Patients must have the psychological ability and general health that permits completion of the study requirements and required follow-up.
- •Inclusion of COVID-19 positive patients will be based on standard institutional protocol.
- •Female patients must meet one of the following:
- •Postmenopausal for at least one year before the screening visit, OR
- •Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
排除标准
- •Radiographic evidence of extranodal extension.
- •Patients with laryngeal involvement who are candidates for non-surgical laryngeal preservation as deemed by a surgeon and/or radiation oncologist. These patients include, but are not limited to, those with T1-T3 laryngeal cancer who do not have pretreatment tracheostomy and/or feeding tube or those with base of tongue/hypopharyngeal cancers with laryngeal involvement without cartilage invasion or pretreatment tracheostomy and/or feeding tube.
- •HPV-positive squamous cell carcinoma.
- •Prior invasive malignancy within the past three years (except for non-melanomatous skin cancer, and early stage treated prostate cancer).
- •Life expectancy less than 12 months.
- •Zubrod performance status ≥
- •Patients with prior radiation therapy to the head and neck (Note: Prior external beam radiotherapy is excluded, but iodine-131 is allowed).
- •Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer.
- •Body weight ≤ 30 kg.
- •Any of the following severe laboratory abnormalities within 14 days of registration, unless corrected prior to it: sodium \< 130 mmol/L or \> 155 mmol/L; potassium \< 3.5 mmol/L or \> 6 mmol/L; fasting glucose \< 40 mg/dL or \> 400 mg/dL; serum calcium (ionized or adjusted for albumin) \< 7 mg/dL or \> 12.5 mg/dL; magnesium \< 0.9 mg/dL or \> 3 mg/dL.
研究组 & 干预措施
46 Gray (Gy)
46 gy of radiation therapy will be administered in 10 fractions.
干预措施: 46 Gy Radiation Therapy
40 Gray (Gy)
40 gy of radiation therapy will be administered in 7 fractions.
干预措施: 40 Gy Radiation Therapy
35 Gray (Gy)
35 gy of radiation therapy will be administered in 5 fractions.
干预措施: 35 Gy Radiation Therapy
结局指标
主要结局
The number of subjects with a dose-limiting toxicity related to perioperative complication rates.
时间窗: 8 Weeks
Severe perioperative complication rates, defined as unacceptable toxicity from initiation of treatment until 30 days postoperatively (grade 4/5 toxicity) probably or definitely related to treatment.
The number of subjects with severe delayed toxicity.
时间窗: Up to one year
Severe delayed toxicities, defined as any unacceptable toxicity (grade 4+) after 30 days postoperatively until one year after initiation of HyPR-HN probably or definitely related to treatment.
The number of subjects with a dose-limiting toxicity related to inoperability.
时间窗: 8 Weeks
Inoperability after HyPR-HN, is defined as an inability to proceed to surgery within eight weeks of radiation.
次要结局
- Overall survival(One year)
- Recurrence-free Survival(One year)